These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 170801)

  • 1. Differential inhibition of phosphodiesterase according to the organ origin of the enzyme.
    Uzunov P; Petkov V; Stancheva S
    Acta Neurobiol Exp (Wars); 1975; 35(2):159-64. PubMed ID: 170801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of phosphodiesterase inhibitors, imidazole and phosphate on cyclic CMP phosphodiesterase are different from those on cyclic AMP and cyclic GMP phosphodiesterases.
    Kuo JF; Shoji M; Brackett NL; Helfman DM
    J Cyclic Nucleotide Res; 1978 Dec; 4(6):463-74. PubMed ID: 85641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on the phosphodiesterase in various organs of rats and guinea-pigs of different ages and different sex.
    Petkov V; Stancheva S
    Acta Physiol Pharmacol Bulg; 1977; 3(1):38-45. PubMed ID: 197791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Actions of various methylxanthines and papaverine on the synthesis of corticosterone in vitro.
    Vapaatalo H; Neuvonen PJ; Bieck P; Westermann E
    Arzneimittelforschung; 1975 Aug; 25(8):1265-9. PubMed ID: 170947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of papaverine on synaptic transmission in the guinea-pig ileum.
    Izzo AA; Mascolo N; Costa M; Capasso F
    Br J Pharmacol; 1997 Jun; 121(4):768-72. PubMed ID: 9208146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological and biochemical study in ontogenetic aspect of 3'-5'-adenosinemonophosphate phosphodiesterases with low and high Km.
    Stancheva S
    Acta Physiol Pharmacol Bulg; 1981; 7(2):69-78. PubMed ID: 6274154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of cyclic AMP phosphodiesterase inhibitors on cardiac sarcolemmal 5'-nucleotidase.
    Heyliger CE; Panagia V; Dhalla NS
    J Pharmacol Exp Ther; 1981 May; 217(2):489-93. PubMed ID: 6262487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of different phosphodiesterase-inhibiting drugs on human pregnant myometrium: an in vitro study.
    Berg G; Andersson RG; Ryden G
    Arch Int Pharmacodyn Ther; 1987 Dec; 290(2):288-92. PubMed ID: 3446047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of adenosine 3',5'-monophosphate phosphodiesterase by nicotinamide and its homologues in vitro.
    Shimoyama M; Kawai M; Nasu S; Shioji K; Hoshi Y
    Physiol Chem Phys; 1975; 7(2):125-32. PubMed ID: 239431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulators of cyclic AMP systems.
    Hess SM; Chasin M; Free CA; Harris DN
    Adv Biochem Psychopharmacol; 1975; (14):153-67. PubMed ID: 242200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Porcine detrusor cyclic nucleotide phosphodiesterase isoenzymes: characterization and functional effects of various phosphodiesterase inhibitors in vitro.
    Truss MC; Uckert S; Stief CG; Schulz-Knappe P; Hess R; Forssmann WG; Jonas U
    Urology; 1995 May; 45(5):893-901. PubMed ID: 7747383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase inhibition as a mechanism for the diuretic activity of 1 ((tert-butylimino)methyl)-2-(3-indolyl)indoline hydrochloride (MJ-8592-1).
    Amer MS; Gomoll AW; McKinney GR
    Res Commun Chem Pathol Pharmacol; 1972 Sep; 4(2):467-76. PubMed ID: 4342315
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of adenyl-cyclase activators, phosphodiesterase inhibitors and pyridoxal-5-phosphate on platelet aggregation and adenosine-3'-5'-cyclic monophosphate accumulation.
    Zahavi M; Zahavi J; Kakkar VV
    Thromb Haemost; 1984 Oct; 52(2):205-9. PubMed ID: 6098048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential activation and inhibition of the multiple forms of cyclic nucleotide phosphodiesterase.
    Weiss B
    Adv Cyclic Nucleotide Res; 1975; 5():195-211. PubMed ID: 165666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The absence of stimulation of lipolysis by papaverine, a strong inhibitor of phosphodiesterase.
    Hynie S; Wenke M
    Eur J Pharmacol; 1975 Feb; 30(2):230-7. PubMed ID: 165081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bronchodilator mechanisms in bullfrog lung: differences in response to isoproterenol, theophylline and papaverine.
    Taylor SM; Downes H
    J Pharmacol Exp Ther; 1982 Nov; 223(2):359-67. PubMed ID: 6290638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effects of two phosphodiesterase inhibitors, theophylline and papaverine, on blood glucose, plasma FFA and glycerol in the rat.
    Mäkeläinen A; Vapaatalo H; Nikki P
    Arzneimittelforschung; 1973 Jun; 23(6):882-3. PubMed ID: 4353588
    [No Abstract]   [Full Text] [Related]  

  • 18. Structure-activity relationships for inhibitors of phosphodiesterase from erythrocytes and other tissues.
    Sheppard H; Wiggan G; Tsien WH
    Adv Cyclic Nucleotide Res; 1972; 1():103-12. PubMed ID: 4354559
    [No Abstract]   [Full Text] [Related]  

  • 19. Pulmonary antiallergic and bronchodilator effects of isozyme-selective phosphodiesterase inhibitors in guinea pigs.
    Howell RE; Sickels BD; Woeppel SL
    J Pharmacol Exp Ther; 1993 Feb; 264(2):609-15. PubMed ID: 8437112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of guanylate cyclases by methylxanthines and papaverine.
    Strinden ST; Stellwagen RH
    Biochem Biophys Res Commun; 1984 Sep; 123(3):1194-200. PubMed ID: 6207821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.